| 15.84 -0.36 (-2.22%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.15  |
1-year : | 21.71 |
| Resists | First : | 17.25 |
Second : | 18.59 |
| Pivot price | 16.31 |
|||
| Supports | First : | 15.1 | Second : | 12.56 |
| MAs | MA(5) : | 16.29 |
MA(20) : | 16.65 |
| MA(100) : | 16.76 |
MA(250) : | 14.27  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 36.6 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 21.45 | Low : | 9.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NVCR ] has closed above bottom band by 30.7%. Bollinger Bands are 40.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.34 - 16.43 | 16.43 - 16.53 |
| Low: | 15.47 - 15.57 | 15.57 - 15.68 |
| Close: | 16 - 16.18 | 16.18 - 16.38 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Thu, 24 Sep 2026
Is NovoCure (NVCR) Undervalued On TTFields Validation And Board Change? - simplywall.st
Thu, 24 Sep 2026
NovoCure Limited (NVCR) Stock Price, News, Quote & History - ca.finance.yahoo.com
Wed, 23 Sep 2026
NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall - Yahoo Finance Singapore
Tue, 22 Sep 2026
NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change - Yahoo Finance
Sun, 20 Sep 2026
Growth Plan Might Change The Case For Investing In NovoCure Stock (NVCR) - simplywall.st
Thu, 17 Sep 2026
Is It Too Late to Buy NovoCure Ltd (NVCR) After 3.1% Rally? GF V - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 116 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 90.7 (%) |
| Shares Short | 9,170 (K) |
| Shares Short P.Month | 11,460 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.9 |
| Profit Margin | -21.3 % |
| Operating Margin | -5.8 % |
| Return on Assets (ttm) | -9.3 % |
| Return on Equity (ttm) | -43.3 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 4.58 |
| Sales Per Share | 6 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 23 (M) |
| PE Ratio | -12.19 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 2.63 |
| Price to Cash Flow | -656.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|